<?xml version="1.0" ?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title><![CDATA[NanoBioMaterials]]></title>
    <link>https://mp.weixin.qq.com/</link>
    <description><![CDATA[NanoBioMaterials公众号]]></description>
    <language>zh-cn</language>
    <image>
      <url>https://raw.githubusercontent.com/osnsyc/Wechat-Scholar/refs/heads/main/icon/gh_a7cdb5705ebf.jpg</url>
      <title>gh_a7cdb5705ebf</title>
    </image>
    <item>
      <title><![CDATA[【Nature Biomedical Engineering】通过Mannich反应构建用于mRNA递送的新型抗氧化离子化脂质库]]></title>
      <description><![CDATA[<img referrerpolicy="no-referrer" src="https://mmbiz.qpic.cn/mmbiz_jpg/HVJRsBachxIUJSVrgfbk4ibuB31iah38Y3VOIhY87Nh64Dx3PHckWGWIXyc42xuzU6p5weJakHXCvfodbR7nicOyQ/640?wxtype=jpeg&amp;wxfrom=0"/><p>在mRNA疗法和疫苗领域，脂质纳米颗粒（LNPs）作为递送载体已展现出巨大潜力，但其固有的高免疫原性限制了蛋白表达的持久性和治疗效果。近日，宾夕法尼亚大学Michael J. Mitchell团队在《</p> ]]></description>
      <link>http://mp.weixin.qq.com/s?__biz=MzI3OTk0OTU2Mg==&amp;mid=2247491247&amp;idx=1&amp;sn=86030dfdbb78ac0817decf604b094ef8&amp;chksm=ea92bc7bc5eef47684fbccec51c080d58d7670266dc6775e948c7b9cf695cc6878be5242502f&amp;scene=0&amp;xtrack=1#rd</link>
      <pubDate>Tue, 22 Jul 2025 02:56:01 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[【Nature Communications】攻克慢性肺炎“反应原性”难题：一种新型非炎性mRNA递送平台]]></title>
      <description><![CDATA[<img referrerpolicy="no-referrer" src="https://mmbiz.qpic.cn/mmbiz_jpg/HVJRsBachxIUJSVrgfbk4ibuB31iah38Y3j21fzOAUO488BGB9gNzsu0ibxDCl4oYZXAF2ScE7JFRibVLnr3uokt4A/640?wxtype=jpeg&amp;wxfrom=0"/><p>mRNA疗法作为近年来生物医药领域最火热的技术之一，已在新冠疫苗的推广中证明了其潜力。但将其进一步应用于慢性疾病治疗，尤其是肺部炎症性疾病，仍面临巨大挑战：现有mRNA脂质纳米颗粒（LNP）递送体系虽</p> ]]></description>
      <link>http://mp.weixin.qq.com/s?__biz=MzI3OTk0OTU2Mg==&amp;mid=2247491242&amp;idx=1&amp;sn=950cddf9b0fa23f29bf544b41a566cee&amp;chksm=ea8a81bfeba160355e382cbfd5bcb0e9b093d184af87008a603059c93a2a17beca931d51a7a7&amp;scene=0&amp;xtrack=1#rd</link>
      <pubDate>Mon, 21 Jul 2025 03:35:30 +0000</pubDate>
    </item>
  </channel>
</rss>